Broad guidelines and a lack of approved therapies results in physicians using a high number of unique treatments in NASH patients.
By Jack Allen, Analyst
4 October 2016
I am an analyst at Datamonitor Healthcare based in the New York office, where I am currently a member of the cardiovascu...
Read full bio
Physicians use a high number of unique treatment regimens to treat patients with non-alcoholic fatty liver disease (NAFLD) in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). This is likely to be the result of broad treatment guidelines and the exclusive use of off-label therapies in this indication; all therapies prescribed to NAFLD patients are prescribed off-label, as there are currently no approved therapies in this indication. Datamonitor Healthcare’s primary research data show that physicians in the US and France prescribe the largest number of unique treatment regimens to their non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver (NAFL) patients (22 regimens), followed by physicians in Germany (21), Italy (19), Spain (18), Japan (14), and the UK (11).
Rates of monotherapy and combination therapy usage by physicians also varied by country. The primary research data show that the majority of physicians treating NASH and NAFL patients use both monotherapies and combination therapies (78.5%). For more information about the specific regimens utilized by physicians in the treatment of NAFL and NASH in each of the surveyed markets (US, Japan, France, Germany, Italy, Spain, and the UK) please inquire about the NASH content.
Datamonitor Healthcare’s NASH treatment: Datamonitor Healthcare’s NASH treatment provides insight into NASH diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision-making, and key treatment challenges.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>